首页 > 最新文献

The American journal of the medical sciences最新文献

英文 中文
ACEI/ARB use within one year of kidney transplant is associated with less AKI and graft loss in elderly recipients. 肾移植后一年内使用 ACEI/ARB 可减少老年受者的 AKI 和移植物丢失。
Pub Date : 2024-07-05 DOI: 10.1016/j.amjms.2024.07.009
A Daoud, K Soliman, D Rodriguez, P Amaechi, T Fulop, D Taber, Ma Posadas Salas

Background: Optimizing long-term graft survival remains a major focus in transplant. Elderly kidney transplant recipients are vulnerable to acute kidney injury (AKI) and graft loss. This study assessed the safety and efficacy of ACEI/ARB in elderly kidney transplant recipients and impact on graft outcomes.

Methods: Retrospective, longitudinal, cohort study of 500 patients age ≥60 years, who underwent kidney transplantation between 2005 and 2015. Demographic, transplant, and outcomes data were collected. Manual chart abstraction was conducted to determine medication use at discharge, one, three, and five years post-transplant. Univariate and multivariable Cox regression modeling were used to analyze outcomes.

Results: Mean age of subjects was 66 years (range 60-81). 59% were males and 50% were African-American. 49% had chronic kidney disease (CKD) due to diabetes mellitus (DM). A total of 38, 134, 167, and 112 elderly kidney transplant recipients were on ACEI/ARB at discharge, one, three, and five years post-transplant respectively. ACEI/ARB initiated within one year of transplant was associated with lower risk of graft loss (HR=0.62, CI 0.38-0.99, p = 0.047). This was driven mainly by a lower risk of death (HR=0.41, CI 0.24-0.71, p = 0.002). ACEI/ARB use was associated with lower risk of AKI after 1 year (HR 0.70, CI 0.52-0.95, p = 0.02). ACEI/ARB was not associated with increased risk of acute rejection or hospitalization.

Conclusion: Initiation of ACEI/ARB within one year of transplant is associated with lower risk of AKI and graft loss, driven by lower risk of death in elderly kidney transplant recipients. Clinicians should maximize ACEI/ARB therapy early on after kidney transplant.

背景:优化长期移植物存活率仍是移植手术的重点。老年肾移植受者容易发生急性肾损伤(AKI)和移植物丢失。本研究评估了 ACEI/ARB 在老年肾移植受者中的安全性和有效性以及对移植物预后的影响:方法:对 2005-2015 年间接受肾移植的 500 名年龄≥60 岁的患者进行回顾性纵向队列研究。收集了人口统计学、移植和预后数据。人工抽取病历以确定出院时、移植后一年、三年和五年的用药情况。采用单变量和多变量考克斯回归模型分析结果:受试者的平均年龄为 66 岁(60-81 岁不等)。59%为男性,50%为非裔美国人。49%的受试者因糖尿病(DM)而患有慢性肾病(CKD)。分别有 38、134、167 和 112 名老年肾移植受者在出院时、移植后一年、三年和五年服用 ACEI/ARB。移植后一年内开始使用 ACEI/ARB 与较低的移植物丢失风险相关(HR=0.62,CI 0.38-0.99,P=0.047)。这主要是由于死亡风险较低(HR=0.41,CI 0.24-0.71,P=0.002)。使用 ACEI/ARB 与 1 年后较低的 AKI 风险相关(HR=0.70,CI=0.52-0.95,P=0.02)。ACEI/ARB与急性排斥反应或住院风险的增加无关:结论:在移植后一年内开始使用 ACEI/ARB 与较低的 AKI 和移植物丢失风险有关,这与老年肾移植受者较低的死亡风险有关。临床医生应在肾移植术后早期尽量使用 ACEI/ARB 治疗。
{"title":"ACEI/ARB use within one year of kidney transplant is associated with less AKI and graft loss in elderly recipients.","authors":"A Daoud, K Soliman, D Rodriguez, P Amaechi, T Fulop, D Taber, Ma Posadas Salas","doi":"10.1016/j.amjms.2024.07.009","DOIUrl":"10.1016/j.amjms.2024.07.009","url":null,"abstract":"<p><strong>Background: </strong>Optimizing long-term graft survival remains a major focus in transplant. Elderly kidney transplant recipients are vulnerable to acute kidney injury (AKI) and graft loss. This study assessed the safety and efficacy of ACEI/ARB in elderly kidney transplant recipients and impact on graft outcomes.</p><p><strong>Methods: </strong>Retrospective, longitudinal, cohort study of 500 patients age ≥60 years, who underwent kidney transplantation between 2005 and 2015. Demographic, transplant, and outcomes data were collected. Manual chart abstraction was conducted to determine medication use at discharge, one, three, and five years post-transplant. Univariate and multivariable Cox regression modeling were used to analyze outcomes.</p><p><strong>Results: </strong>Mean age of subjects was 66 years (range 60-81). 59% were males and 50% were African-American. 49% had chronic kidney disease (CKD) due to diabetes mellitus (DM). A total of 38, 134, 167, and 112 elderly kidney transplant recipients were on ACEI/ARB at discharge, one, three, and five years post-transplant respectively. ACEI/ARB initiated within one year of transplant was associated with lower risk of graft loss (HR=0.62, CI 0.38-0.99, p = 0.047). This was driven mainly by a lower risk of death (HR=0.41, CI 0.24-0.71, p = 0.002). ACEI/ARB use was associated with lower risk of AKI after 1 year (HR 0.70, CI 0.52-0.95, p = 0.02). ACEI/ARB was not associated with increased risk of acute rejection or hospitalization.</p><p><strong>Conclusion: </strong>Initiation of ACEI/ARB within one year of transplant is associated with lower risk of AKI and graft loss, driven by lower risk of death in elderly kidney transplant recipients. Clinicians should maximize ACEI/ARB therapy early on after kidney transplant.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141556328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term trends in lifestyle factors among respondents with dyslipidemia in the United States. 美国血脂异常受访者生活方式因素的长期趋势。
Pub Date : 2024-07-05 DOI: 10.1016/j.amjms.2024.06.025
Bingqing Bai, Quanjun Liu, Yuting Liu, Fengyao Liu, Yu Wang, Yilin Chen, Yanting Liang, Haochen Wang, Chao Wu, Lan Guo, Huan Ma, Qingshan Geng

Objectives: To explore the long-term trends in unhealthy lifestyle factors and the risk sociodemographic subgroups among people with dyslipidemia.

Methods: Data extracted from the 1999 to 2018 National Health and Nutrition Examination Survey (NHANES). Lifestyle factors were smoking status, alcohol drinking, obesity, dietary quality, depression, physical activity, and sedentary behavior. A Joinpoint regression model was used to estimate trends in the log-transformed age-standardized prevalence. Multinomial logistic regression models adjusted for age, sex, and race/ethnicity were used to analyze subgroups by sociodemographic factors.

Results: Data for 33,680 respondents were extracted between 1999 and 2018. The prevalence of smoking and poor-quality diet decreased from 1999 to 2018 (P<0.001), while obesity significantly increased (P<0.001). The prevalence of depression marginally increased from 2005 to 2018 (P=0.074). We observed that non-Hispanic Black individuals, Hispanics, males, as well as those with lower family income-to-poverty ratios and education levels, unemployed individuals, or those lacking a spouse/live-in partner, were at elevated risk of unhealthy lifestyle factors when compared to the reference groups.

Conclusions: Among NHANES respondents from 1999 to 2018 with dyslipidemia, significant reductions in the prevalence of current smoking and poor diet were observed, while the prevalence of obesity was markedly increased. There were sociodemographic differences in the management of lifestyle factors. Further initiatives to encourage people with dyslipidemia are required to reduce potential adverse outcomes.

目的探讨不健康生活方式因素的长期趋势以及血脂异常人群中的风险社会人口亚群:从 1999 年至 2018 年美国国家健康与营养调查(NHANES)中提取数据。生活方式因素包括吸烟状况、饮酒、肥胖、饮食质量、抑郁、体力活动和久坐行为。接合点回归模型用于估计对数变换年龄标准化患病率的趋势。根据年龄、性别和种族/人种调整后的多项式逻辑回归模型用于分析社会人口因素的分组情况:提取了 1999 年至 2018 年间 33680 名受访者的数据。从 1999 年到 2018 年,吸烟和劣质饮食的流行率有所下降(P 结论:从 1999 年到 2018 年,吸烟和劣质饮食的流行率有所下降:在 1999-2018 年患有血脂异常的 NHANES 受访者中,观察到当前吸烟率和不良饮食率显著下降,而肥胖率明显上升。在管理生活方式因素方面存在社会人口差异。需要采取进一步措施鼓励血脂异常患者,以减少潜在的不良后果。
{"title":"Long-term trends in lifestyle factors among respondents with dyslipidemia in the United States.","authors":"Bingqing Bai, Quanjun Liu, Yuting Liu, Fengyao Liu, Yu Wang, Yilin Chen, Yanting Liang, Haochen Wang, Chao Wu, Lan Guo, Huan Ma, Qingshan Geng","doi":"10.1016/j.amjms.2024.06.025","DOIUrl":"10.1016/j.amjms.2024.06.025","url":null,"abstract":"<p><strong>Objectives: </strong>To explore the long-term trends in unhealthy lifestyle factors and the risk sociodemographic subgroups among people with dyslipidemia.</p><p><strong>Methods: </strong>Data extracted from the 1999 to 2018 National Health and Nutrition Examination Survey (NHANES). Lifestyle factors were smoking status, alcohol drinking, obesity, dietary quality, depression, physical activity, and sedentary behavior. A Joinpoint regression model was used to estimate trends in the log-transformed age-standardized prevalence. Multinomial logistic regression models adjusted for age, sex, and race/ethnicity were used to analyze subgroups by sociodemographic factors.</p><p><strong>Results: </strong>Data for 33,680 respondents were extracted between 1999 and 2018. The prevalence of smoking and poor-quality diet decreased from 1999 to 2018 (P<0.001), while obesity significantly increased (P<0.001). The prevalence of depression marginally increased from 2005 to 2018 (P=0.074). We observed that non-Hispanic Black individuals, Hispanics, males, as well as those with lower family income-to-poverty ratios and education levels, unemployed individuals, or those lacking a spouse/live-in partner, were at elevated risk of unhealthy lifestyle factors when compared to the reference groups.</p><p><strong>Conclusions: </strong>Among NHANES respondents from 1999 to 2018 with dyslipidemia, significant reductions in the prevalence of current smoking and poor diet were observed, while the prevalence of obesity was markedly increased. There were sociodemographic differences in the management of lifestyle factors. Further initiatives to encourage people with dyslipidemia are required to reduce potential adverse outcomes.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141556330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gut barrier dysfunction, endotoxemia and inflammatory response in STEMI patients and effect of primary PCI. STEMI 患者肠道屏障功能障碍、内毒素血症和炎症反应以及初级 PCI 的影响。
Pub Date : 2024-07-04 DOI: 10.1016/j.amjms.2024.07.004
Ioanna Oikonomou, Angeliki Papageorgiou, Anne-Lise de Lastic, Athanasios Moulias, Georgia-Andriana Georgopoulou, Athanasia Mouzaki, Eleni-Evangelia Koufou, Grigorios Tsigkas, Charalambos Gogos, Periklis Davlouros, Stelios F Assimakopoulos

Background: Gut-derived bacterial and endotoxin translocation induce systemic inflammation, which exerts a pivotal pathogenetic role in all phases of atherosclerosis.

Objectives: To investigate prospectively the gut barrier function, endotoxin translocation and inflammatory response in ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary artery intervention (PPCI).

Methods: Twenty-seven patients with STEMI that underwent successful PPCI were subjected to peripheral blood sampling at 3-time points; before PPCI (day0), 24 h (day1) and 96 h (day4) after PPCI and were compared with 20 chronic coronary syndrome (CCS) patients and 11 healthy controls. Serum ZO-1, I-FABP and endotoxin concentrations were determined by ELISA. Concentrations of cytokines IL-1β, -6, -8, -10 and TNF-α were determined by flow cytometry.

Results: Patients with STEMI before PPCI (day0) had increased serum ZO-1 and endotoxin, both at significantly higher levels compared to CCS patients. STEMI induced also significant increases of the cytokines IL-6, -8 and -10. After PPCI, a significant improvement of gut barrier integrity (ZO-1) and endotoxemia was observed from the first day. At day4 post PPCI, systemic endotoxin and cytokines IL-6, -8 and -10 levels were reduced to control levels. Serum ZO-1 levels were positively correlated with systemic IL-10 concentrations (r = 0.471).

Conclusion: STEMI is associated with gut barrier dysfunction, systemic endotoxemia and inflammatory response, which improve rapidly following successful PPCI.

背景:源于肠道的细菌和内毒素转运诱发全身炎症:肠道细菌和内毒素转运会诱发全身炎症,而炎症在动脉粥样硬化的各个阶段都起着关键的致病作用:目的:对接受经皮冠状动脉介入治疗(PPCI)的ST段抬高型心肌梗死(STEMI)患者的肠道屏障功能、内毒素转运和炎症反应进行前瞻性研究:对成功接受经皮冠状动脉介入治疗的 27 例 STEMI 患者在三个时间点(经皮冠状动脉介入治疗前(第 0 天)、经皮冠状动脉介入治疗后 24 小时(第 1 天)和经皮冠状动脉介入治疗后 96 小时(第 4 天))进行外周血采样,并与 20 例慢性冠状动脉综合征(CCS)患者和 11 例健康对照组进行比较。血清 ZO-1、I-FABP 和内毒素浓度由 ELISA 法测定。通过流式细胞术测定细胞因子 IL-1β、-6、-8、-10 和 TNF-α 的浓度:结果:PPCI 前(第 0 天)STEMI 患者的血清 ZO-1 和内毒素水平均显著高于 CCS 患者。STEMI 还导致细胞因子 IL-6、-8 和 -10 显著增加。做完冠状动脉造影术后,肠道屏障完整性(ZO-1)和内毒素血症从第一天起就得到了明显改善。在实施 PPCI 后的第 4 天,全身内毒素和细胞因子 IL-6、-8 和 -10 水平已降至对照组水平。血清 ZO-1 水平与全身 IL-10 浓度呈正相关(r=0.471)。在 STEMI 患者中,PPCI 前(第 0 天)的血清内毒素浓度与出院时的射血分数(EF)呈负相关:结论:STEMI 与肠道屏障功能障碍、全身内毒素血症和炎症反应有关,这些症状在成功进行心肺复苏术后会迅速改善。
{"title":"Gut barrier dysfunction, endotoxemia and inflammatory response in STEMI patients and effect of primary PCI.","authors":"Ioanna Oikonomou, Angeliki Papageorgiou, Anne-Lise de Lastic, Athanasios Moulias, Georgia-Andriana Georgopoulou, Athanasia Mouzaki, Eleni-Evangelia Koufou, Grigorios Tsigkas, Charalambos Gogos, Periklis Davlouros, Stelios F Assimakopoulos","doi":"10.1016/j.amjms.2024.07.004","DOIUrl":"10.1016/j.amjms.2024.07.004","url":null,"abstract":"<p><strong>Background: </strong>Gut-derived bacterial and endotoxin translocation induce systemic inflammation, which exerts a pivotal pathogenetic role in all phases of atherosclerosis.</p><p><strong>Objectives: </strong>To investigate prospectively the gut barrier function, endotoxin translocation and inflammatory response in ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary artery intervention (PPCI).</p><p><strong>Methods: </strong>Twenty-seven patients with STEMI that underwent successful PPCI were subjected to peripheral blood sampling at 3-time points; before PPCI (day0), 24 h (day1) and 96 h (day4) after PPCI and were compared with 20 chronic coronary syndrome (CCS) patients and 11 healthy controls. Serum ZO-1, I-FABP and endotoxin concentrations were determined by ELISA. Concentrations of cytokines IL-1β, -6, -8, -10 and TNF-α were determined by flow cytometry.</p><p><strong>Results: </strong>Patients with STEMI before PPCI (day0) had increased serum ZO-1 and endotoxin, both at significantly higher levels compared to CCS patients. STEMI induced also significant increases of the cytokines IL-6, -8 and -10. After PPCI, a significant improvement of gut barrier integrity (ZO-1) and endotoxemia was observed from the first day. At day4 post PPCI, systemic endotoxin and cytokines IL-6, -8 and -10 levels were reduced to control levels. Serum ZO-1 levels were positively correlated with systemic IL-10 concentrations (r = 0.471).</p><p><strong>Conclusion: </strong>STEMI is associated with gut barrier dysfunction, systemic endotoxemia and inflammatory response, which improve rapidly following successful PPCI.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141539116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Single nucleotide polymorphisms of GEMIN3 modify the risk of primary Sjögren's syndrome in female patients. GEMIN3 的单核苷酸多态性改变了女性患者罹患原发性斯约格伦综合征的风险。
Pub Date : 2024-07-04 DOI: 10.1016/j.amjms.2024.07.001
Dong Wang, Jingjing Zhang, Yufei Zhao, Ruijie Cao, Yingnan Wang, Iren Guo, Chenxing Peng, Yanrong Song, Shasha Zhang

Background: MicroRNA (miRNA)-processing machinery may modify the risk of primary Sjögren's syndrome (pSS) by altering miRNA expression profiles. Inflammatory cytokines and reactive oxygen species (ROS) are also involved in pSS; however, the role of altered miRNAs expression in its pathogenesis is still unclear. We aimed to evaluate the relationship between single-nucleotide polymorphisms (SNPs) in miRNA processing machinery genes, including XPO5 (rs11077), RAN (rs14035), Dicer (rs3742330), TNRC6B (rs9623117), GEMIN3 (rs197412), and GEMIN4 (rs2740348), and the risk of pSS in female patients. The potential associations of cytokines and ROS with pSS-susceptible SNPs were also evaluated.

Materials and methods: The SNPs confirmed by polymerase chain reaction ligase detection reaction were genotyped in 74 female patients with pSS and 77 controls. The relationship was analyzed by Student's t-test, Wilcoxon rank-sum test, chi-square test, Pearson's correlation test, and binary logistic regression analysis.

Results: For rs197412 of the GEMIN3 gene, the genotype TT carrier was associated with a 2.172-fold increased risk for pSS when compared with that of CT+CC carrier (odds ratio: 2.172, 95% CI, 1.133-4.166, p=0.019). Simultaneously, the pSS-susceptible TT carriers were associated with increased interferon-γ (IFN-γ) (P < 0.001) and tumor necrosis factor-α (TNF-α) (P = 0.003) levels when compared with that of CT+CC genotype carriers in female patients with pSS. The subsequent analysis also showed a weak positive correlation between IFN-γ and TNF-α levels (r=0.271, P = 0.019).

Conclusion: The predictors of GEMIN3 SNPs might modify pSS development in females by mediating the expression of miRNAs and therefore regulate the levels of IFN-γ and TNF-α.

背景:微RNA(miRNA)处理机制可通过改变miRNA的表达谱来改变原发性斯约格伦综合征(pSS)的发病风险。炎性细胞因子和活性氧(ROS)也与 pSS 有关;然而,miRNAs 表达的改变在其发病机制中的作用仍不清楚。我们旨在评估 miRNA 处理机制基因(包括 XPO5 (rs11077)、RAN (rs14035)、Dicer (rs3742330)、TNRC6B (rs9623117)、GEMIN3 (rs197412) 和 GEMIN4 (rs2740348))中的单核苷酸多态性 (SNPs) 与女性患者 pSS 风险之间的关系。此外,还评估了细胞因子和 ROS 与 pSS 易感 SNPs 的潜在关联:方法:在 74 名女性 pSS 患者和 77 名对照者中,对聚合酶链反应连接酶检测反应证实的 SNPs 进行基因分型。通过学生 t 检验、Wilcoxon 秩和检验、秩和检验、Pearson 相关性检验和二元逻辑回归分析对两者之间的关系进行了分析:GEMIN3 基因 rs197412 的基因型 TT 携带者与 CT+CC 携带者相比,患 pSS 的风险增加了 2.172 倍(几率比:2.172,95% CI,1.133-4.166,P=0.019)。同时,易感 pSS 的 TT 携带者与干扰素-γ(IFN-γ)的增加有关(PC结论:GEMIN3 SNPs的预测因子可能会通过介导miRNAs的表达来改变女性pSS的发展,从而调节IFN-γ和TNF-α的水平。
{"title":"Single nucleotide polymorphisms of GEMIN3 modify the risk of primary Sjögren's syndrome in female patients.","authors":"Dong Wang, Jingjing Zhang, Yufei Zhao, Ruijie Cao, Yingnan Wang, Iren Guo, Chenxing Peng, Yanrong Song, Shasha Zhang","doi":"10.1016/j.amjms.2024.07.001","DOIUrl":"10.1016/j.amjms.2024.07.001","url":null,"abstract":"<p><strong>Background: </strong>MicroRNA (miRNA)-processing machinery may modify the risk of primary Sjögren's syndrome (pSS) by altering miRNA expression profiles. Inflammatory cytokines and reactive oxygen species (ROS) are also involved in pSS; however, the role of altered miRNAs expression in its pathogenesis is still unclear. We aimed to evaluate the relationship between single-nucleotide polymorphisms (SNPs) in miRNA processing machinery genes, including XPO5 (rs11077), RAN (rs14035), Dicer (rs3742330), TNRC6B (rs9623117), GEMIN3 (rs197412), and GEMIN4 (rs2740348), and the risk of pSS in female patients. The potential associations of cytokines and ROS with pSS-susceptible SNPs were also evaluated.</p><p><strong>Materials and methods: </strong>The SNPs confirmed by polymerase chain reaction ligase detection reaction were genotyped in 74 female patients with pSS and 77 controls. The relationship was analyzed by Student's t-test, Wilcoxon rank-sum test, chi-square test, Pearson's correlation test, and binary logistic regression analysis.</p><p><strong>Results: </strong>For rs197412 of the GEMIN3 gene, the genotype TT carrier was associated with a 2.172-fold increased risk for pSS when compared with that of CT+CC carrier (odds ratio: 2.172, 95% CI, 1.133-4.166, p=0.019). Simultaneously, the pSS-susceptible TT carriers were associated with increased interferon-γ (IFN-γ) (P < 0.001) and tumor necrosis factor-α (TNF-α) (P = 0.003) levels when compared with that of CT+CC genotype carriers in female patients with pSS. The subsequent analysis also showed a weak positive correlation between IFN-γ and TNF-α levels (r=0.271, P = 0.019).</p><p><strong>Conclusion: </strong>The predictors of GEMIN3 SNPs might modify pSS development in females by mediating the expression of miRNAs and therefore regulate the levels of IFN-γ and TNF-α.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141539118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pamiparib, a novel intervention with anti-neoplastic activity for the treatment of glioblastoma. 帕米帕利(Pamiparib),一种具有抗肿瘤活性的治疗胶质母细胞瘤的新型干预方法。
Pub Date : 2024-07-03 DOI: 10.1016/j.amjms.2024.07.007
Sehar Ul Duaa, Eeshal Fatima, Zaheer Qureshi
{"title":"Pamiparib, a novel intervention with anti-neoplastic activity for the treatment of glioblastoma.","authors":"Sehar Ul Duaa, Eeshal Fatima, Zaheer Qureshi","doi":"10.1016/j.amjms.2024.07.007","DOIUrl":"10.1016/j.amjms.2024.07.007","url":null,"abstract":"","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141539117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ethical consumption of antimicrobial agents: A proposal for a new concept in promoting antimicrobial stewardship. 抗菌剂的道德消费:促进抗菌药物管理的新概念提案。
Pub Date : 2024-07-03 DOI: 10.1016/j.amjms.2024.07.002
Hideharu Hagiya
{"title":"Ethical consumption of antimicrobial agents: A proposal for a new concept in promoting antimicrobial stewardship.","authors":"Hideharu Hagiya","doi":"10.1016/j.amjms.2024.07.002","DOIUrl":"10.1016/j.amjms.2024.07.002","url":null,"abstract":"","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141539115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial intelligence in medicine: Between Saturn and Cronus. 人工智能在医学中的应用:在土星和克洛诺斯之间
Pub Date : 2024-07-02 DOI: 10.1016/j.amjms.2024.06.026
Lucindo José Quintans-Júnior, Adriano Antunes de Souza Araújo, Paulo Ricardo Martins-Filho
{"title":"Artificial intelligence in medicine: Between Saturn and Cronus.","authors":"Lucindo José Quintans-Júnior, Adriano Antunes de Souza Araújo, Paulo Ricardo Martins-Filho","doi":"10.1016/j.amjms.2024.06.026","DOIUrl":"10.1016/j.amjms.2024.06.026","url":null,"abstract":"","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141536307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is 90 the new 80? Temporal trends in nonagenarians undergoing percutaneous coronary interventions. 90 岁是新的 80 岁吗?接受经皮冠状动脉介入治疗的非老年患者的时间趋势。
Pub Date : 2024-07-02 DOI: 10.1016/j.amjms.2024.06.029
Ori Rahat, Mark Kheifets, Tamir Bental, Shelly Abigail Vons, Ori Tishler, Tsahi T Lerman, Caroline Kaufman, Leor Perl, Gabriel Greenberg, Pablo Codner, Guy Witberg, Hana Vaknin-Assa, Ran Kornowski, Amos Levi

Background: Coronary artery disease (CAD) is a leading cause of death in the elderly population. Data regarding percutaneous coronary interventions (PCIs) in nonagenarians are scarce, and differences in long term outcomes between generations remain unclear. We aimed to study the pattern and temporal trends of nonagenarians treated with PCI.

Materials and methods: A total of 14,695 patients underwent PCI between 2009-2020. We identified 2,034 (13.8%) octogenarians (age 80-89), and 222 (1.5%) nonagenarians (age 90-99). Endpoints included mortality and major adverse cardiac events (MACE) at 1 year.

Materials and methods: A total of 14,695 patients underwent PCI between 2009-2020. We identified 2,034 (13.8%) octogenarians (age 80-89), and 222 (1.5%) nonagenarians (age 90-99). Endpoints included mortality and major adverse cardiac events (MACE) at 1 year.

Results: The number of nonagenarians undergoing PCI has increased substantially during the study time period, from 89 patients in the earlier time period (2009-2014) to 133 patients in the later time period (2015-2020). At 1-year, nonagenarians had significantly higher rates of both death (24.3% vs. 14.9%, p<0.01), and MACE (30.6% vs. 22.0%, p<0.01), as compared to octogenarians. The cumulative survival rate was higher among octogenarians both in the early and late time period (p<0.01 and p=0.039, respectively). A significant reduction in nonagenarian MACE rates were observed during the study time period, resulting in a non-significant difference in MACE rates in the later time period between both groups.

Conclusion: The number of nonagenarians who undergo PCI is on the rise. While their clinical outcomes are inferior as compared to younger age groups, improvement was noted in the late time period.

背景:冠状动脉疾病(CAD)是导致老年人死亡的主要原因。有关非老年人经皮冠状动脉介入治疗(PCI)的数据很少,不同年龄段之间的长期疗效差异仍不清楚。我们旨在研究接受 PCI 治疗的非老年患者的模式和时间趋势:2009-2020年间,共有14695名患者接受了PCI治疗。我们确定了 2034 名(13.8%)八旬老人(80-89 岁)和 222 名(1.5%)非耄耋老人(90-99 岁)。终点包括1年的死亡率和主要心脏不良事件(MACE):在研究期间,接受PCI治疗的非老年患者人数大幅增加,从早期(2009-2014年)的89人增加到后期(2015-2020年)的133人。1年后,非长者的死亡率明显高于长者(24.3% vs. 14.9%,pConclusion):接受PCI治疗的非长者人数正在增加。虽然他们的临床结果不如年轻群体,但在晚期有所改善。
{"title":"Is 90 the new 80? Temporal trends in nonagenarians undergoing percutaneous coronary interventions.","authors":"Ori Rahat, Mark Kheifets, Tamir Bental, Shelly Abigail Vons, Ori Tishler, Tsahi T Lerman, Caroline Kaufman, Leor Perl, Gabriel Greenberg, Pablo Codner, Guy Witberg, Hana Vaknin-Assa, Ran Kornowski, Amos Levi","doi":"10.1016/j.amjms.2024.06.029","DOIUrl":"10.1016/j.amjms.2024.06.029","url":null,"abstract":"<p><strong>Background: </strong>Coronary artery disease (CAD) is a leading cause of death in the elderly population. Data regarding percutaneous coronary interventions (PCIs) in nonagenarians are scarce, and differences in long term outcomes between generations remain unclear. We aimed to study the pattern and temporal trends of nonagenarians treated with PCI.</p><p><strong>Materials and methods: </strong>A total of 14,695 patients underwent PCI between 2009-2020. We identified 2,034 (13.8%) octogenarians (age 80-89), and 222 (1.5%) nonagenarians (age 90-99). Endpoints included mortality and major adverse cardiac events (MACE) at 1 year.</p><p><strong>Materials and methods: </strong>A total of 14,695 patients underwent PCI between 2009-2020. We identified 2,034 (13.8%) octogenarians (age 80-89), and 222 (1.5%) nonagenarians (age 90-99). Endpoints included mortality and major adverse cardiac events (MACE) at 1 year.</p><p><strong>Results: </strong>The number of nonagenarians undergoing PCI has increased substantially during the study time period, from 89 patients in the earlier time period (2009-2014) to 133 patients in the later time period (2015-2020). At 1-year, nonagenarians had significantly higher rates of both death (24.3% vs. 14.9%, p<0.01), and MACE (30.6% vs. 22.0%, p<0.01), as compared to octogenarians. The cumulative survival rate was higher among octogenarians both in the early and late time period (p<0.01 and p=0.039, respectively). A significant reduction in nonagenarian MACE rates were observed during the study time period, resulting in a non-significant difference in MACE rates in the later time period between both groups.</p><p><strong>Conclusion: </strong>The number of nonagenarians who undergo PCI is on the rise. While their clinical outcomes are inferior as compared to younger age groups, improvement was noted in the late time period.</p>","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141536308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Monitor-related changes consistent with paradoxical pulse 与矛盾脉搏一致的监护仪相关变化
Pub Date : 2024-07-01 DOI: 10.1016/j.amjms.2024.07.014
Hiroki Matsuura, Masayuki Kishida
{"title":"Monitor-related changes consistent with paradoxical pulse","authors":"Hiroki Matsuura, Masayuki Kishida","doi":"10.1016/j.amjms.2024.07.014","DOIUrl":"https://doi.org/10.1016/j.amjms.2024.07.014","url":null,"abstract":"","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141690841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A rare observation in a case of Williams-Campbell syndrome. 威廉姆斯-坎贝尔综合症病例中的罕见观察结果。
Pub Date : 2024-06-29 DOI: 10.1016/j.amjms.2024.06.031
Chun Ian Soo, Wai Ling Leong, Leng Cheng Sia
{"title":"A rare observation in a case of Williams-Campbell syndrome.","authors":"Chun Ian Soo, Wai Ling Leong, Leng Cheng Sia","doi":"10.1016/j.amjms.2024.06.031","DOIUrl":"10.1016/j.amjms.2024.06.031","url":null,"abstract":"","PeriodicalId":94223,"journal":{"name":"The American journal of the medical sciences","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141478299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
The American journal of the medical sciences
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1